Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CYTHW 
Cyclo Therapeutics Inc (CYTHW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/13/2025: CYTHW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -68.17% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 62.76M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 19296 | Beta -0.57 | 52 Weeks Range 0.03 - 0.36 | Updated Date 02/24/2025 |
52 Weeks Range 0.03 - 0.36 | Updated Date 02/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -3545.95% |
Management Effectiveness
Return on Assets (TTM) -284.27% | Return on Equity (TTM) -22663.91% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 11512688 |
Shares Outstanding - | Shares Floating 11512688 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cyclo Therapeutics Inc
Company Overview
History and Background
Cyclo Therapeutics, Inc. was founded to develop and commercialize cyclodextrin-based products for the treatment of diseases. It has focused on rare diseases and unmet medical needs. Founded on the technology developed at the University of Florida.
Core Business Areas
- Trappsolu00ae Cyclou2122: Development of Trappsolu00ae Cyclou2122, a cyclodextrin drug, for the treatment of Niemann-Pick Disease Type C (NPC) and other diseases.
Leadership and Structure
The company is led by a board of directors and a management team with expertise in drug development and commercialization.
Top Products and Market Share
Key Offerings
- Trappsolu00ae Cyclou2122: Trappsolu00ae Cyclou2122 is Cyclo Therapeutics' primary product candidate, aimed at treating Niemann-Pick Disease Type C (NPC). The market share is still developing as the drug is not yet fully approved. Competitors include companies developing alternative therapies for NPC.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and strong competition. Rare disease treatments have become a growing area of focus.
Positioning
Cyclo Therapeutics is focused on a niche market within the pharmaceutical industry, specifically rare diseases. Their competitive advantage lies in their cyclodextrin technology and their focus on NPC.
Total Addressable Market (TAM)
The TAM for NPC treatment is estimated in the hundreds of millions of dollars annually. Cyclo Therapeutics aims to capture a significant portion of this market with Trappsolu00ae Cyclou2122.
Upturn SWOT Analysis
Strengths
- Proprietary cyclodextrin technology
- Focus on unmet medical needs
- Orphan drug designation for NPC
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on single product candidate
- Regulatory risks associated with drug approval
- Small company size
Opportunities
- Potential for FDA approval of Trappsolu00ae Cyclou2122
- Expansion to other rare disease indications
- Partnerships with larger pharmaceutical companies
- Increasing awareness of rare diseases
Threats
- Competition from other NPC treatments
- Clinical trial failures
- Regulatory delays
- Financing risks
Competitors and Market Share
Key Competitors
- ALKS
- JNJ
- VRTX
Competitive Landscape
Cyclo Therapeutics is a smaller player competing with larger pharmaceutical companies. Their advantage lies in their specific focus on cyclodextrin technology and NPC.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to clinical trial progress and funding success.
Future Projections: Future growth is highly dependent on FDA approval of Trappsolu00ae Cyclou2122 and subsequent market adoption.
Recent Initiatives: Recent initiatives include ongoing clinical trials and efforts to secure regulatory approval.
Summary
Cyclo Therapeutics is a development-stage pharmaceutical company focusing on rare diseases, particularly Niemann-Pick Disease Type C. The company's success hinges on the approval and commercialization of its lead product candidate, Trappsolu00ae Cyclou2122. It faces challenges related to funding, competition, and regulatory hurdles, but also has opportunities for growth through successful clinical trials and partnerships. The company is highly speculative.
Similar Companies
- ALKS
- JNJ
- VRTX
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst research
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cyclo Therapeutics Inc
Exchange NASDAQ | Headquaters Gainesville, FL, United States | ||
IPO Launch date 2020-12-09 | CEO & Director Mr. N. Scott Fine | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 8 | Website https://cyclotherapeutics.com |
Full time employees 8 | Website https://cyclotherapeutics.com | ||
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida. Cyclo Therapeutics, Inc. is a subsidiary of Rafael Holdings, Inc.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.